Genomic classification of pancreatic ductal adenocarcinomas correlated to clinical outcomes

Tumours arising in the pancreas and biliary tree are notorious for their aggressive biological behavior. They all show a similar histomorphology and are difficult to distinguish from one another, while this is essential for subsequent distinct treatments. HPB-biobanking has helped to collect large cohorts of high quality biospecimens with cliniopathological details, which have enabled us to perform gene expression-based, miRNA, and glycan profiling for pancreatic cancer. Immunohistochemistry a.o. helps to further characterize subtypes, and identify biomarkers for subtypes and response to therapy. Diagnostics may also be improved by DNA-based and minimally invasive methods.
Biochemical and DNA-based methods are also deployed to presurgically distinguish between pancreatic cyst types.
Finally, we collaborate in the PANcreatic disease ReseArch (PANDoRA) consortium, which aims to uncover new genetic factors for pancreatic cancer risk and survival